Actively Recruiting
Open-label Phase 12 Study of 90YY-PentixaTher for Treating Recurrent or Refractory CNS Lymphoma with Intravenous Dose Escalation
Led by Pentixapharm AG · Updated on 2026-06-05
15
Participants Needed
2
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of 90YY-PentixaTher 90YY-PTT to treat patients with recurrent or refractory primary or isolated secondary central nervous system CNS lymphoma. This open-label, single-arm phase 12 study aims to evaluate the safety, tolerability, biodistribution, and preliminary effectiveness of this treatment. The study includes three dose-level groups, and a safety review committee will carefully monitor for any dose-limiting side effects to guide dose adjustments. Participants will receive one cycle of 90YY-PTT administered intravenously. The study follows a best-of-5 dose escalation design across three cohorts with different dose levels. There is no comparison group in this study. After the treatment, patients will undergo several visits during the core study phase to assess safety, how the drug spreads in the body, dosimetry, and treatment response. Following this, three follow-up visits will occur at three-month intervals to monitor disease status. Throughout the study, participants will be closely monitored for adverse events, with severity graded by standard criteria. Various imaging and laboratory tests will be performed shortly after infusion and at multiple time points to measure drug uptake in tumors and organs, blood levels, and absorbed radiation doses. Researchers will assess response rates, progression-free survival, and overall survival at one, three, six, nine, and twelve months after treatment. The total study duration includes screening, treatment, core evaluations, and extended follow-up visits to comprehensively evaluate treatment outcomes and safety.
CONDITIONS
Brief Title
[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients
Research Team
S
Simone Pickel
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here